"AI Applications in Biopharma Summit provides a rare opportunity to engage with AI research executives and business stakeholders in pharma and healthcare. Speaker topics are curated with strategic intention, and address the diverse needs of attendees who have a range of technology, business, and scientific backgrounds. This forum offers exclusive content that builds on market analyst reporting, and interviews with pharma leaders who are responsible for digital R&D transformation, clinical innovation, and data science technology advances. Early stage technology and AI solution providers have unfettered access for introductions to both small and large companies. "
VP Business Development, BioSymetrics Inc.
Thanks again for the well-run AI Summit. My colleague and I were able to strengthen our knowledge and contacts in this space.
Director, R&D Information Systems, Gilead Sciences
Great speakers and superbly focused talks. As someone tracking the leading edge of AI in Pharma, I found this meeting to be extremely high-impact.
Managing Partner, Word Control, Co-author, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market
Thank you so much for all your work to make the AI Applications Summit such a success. It was a really great group of people to get together, and a thought provoking set of topics.
Founder & President, Data2Discovery, Inc.
“The organizers have managed to get in one venue many of the leading thinkers and implementors in biopharma AI. Everyone is very approachable and there are plenty of networking and breakout events where you can have one-on-one conversations.”
Director of Data Science and Chief Evangelist, Embedded AI, GSI Technology
Currently, drug discovery is a blind search through chemical libraries, which is not that efficient. The AI Applications Summit is an important gathering of thought leaders to discuss better options, such as generative AI models, which can potentially speed up the drug discovery process by proposing a limited amount of high promising molecules instead of thousands with unknown activities and possibly increase the drug space (finding new drug, a new mechanism of action, new chemistry).
Research Scientist, Pharma AI a division of Insilico Medicine
As an attendee, I found the focus on the healthcare ecosystem for networking with speakers and other participants to be very valuable.
Director, Strategic Alliance Center of Excellence, Merck
A who's who of AI in Pharma, etc.
Founder & CEO, Collaborations Pharmaceuticals, Inc.
"Great group of speakers and participants. Very insightful conversations. Excellent opportunity to network with thought leaders reshaping Pharma industry."
Director, Data Science, Sanofi Pasteur
I thought the meeting was very interesting and established new contacts for my team. Thanks again for all you have done.
Associate Director for Data Mining and Informatics Evaluation and Research , Office of Translational Sciences, Center for Drug Evaluation and Research (CDER) , Food and Drug Administration (FDA)
The much-needed honest discussion of what is hype and what is possible – the challenges, failures and successes of these technologies – was hotly debated at the AI Applications Summit
Associate Vice Chancellor for Informatics, Chief Digital Technology Officer, Director, Center for Digital Health Innovation, Professor of Medicine, Cardiology, University of California, San Francisco
Therapeutic interventions that you can use are where the rubber meets the road. If the results coming from data and its analysis are not actionable, the data is not immediately useful. The fastest way to increase utility is through data sharing. Changing the culture to allow for sharing starts with discussions and debates like those that took place at the AI Applications Summit.
Professor of Biostatistics and Computation Biology, Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health